TransMedics Group Inc (TMDX) - Cash Flow Conversion Efficiency
Based on the latest financial reports, TransMedics Group Inc (TMDX) has a cash flow conversion efficiency ratio of 0.050x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($24.53 Million) by net assets ($494.01 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See TMDX net asset quality index to measure how much of total assets are equity-financed.
TransMedics Group Inc - Cash Flow Conversion Efficiency Trend (2006–2025)
This chart illustrates how TransMedics Group Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check TMDX cash flow quality score to evaluate the quality of earnings relative to operating cash generation.
TransMedics Group Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of TransMedics Group Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Enliven Therapeutics Inc.
NASDAQ:ELVN
|
-0.043x |
|
Meitu Inc
F:M5U
|
0.013x |
|
Poco Holding Co Ltd
SHE:300811
|
0.018x |
|
Atkore International Group Inc
NYSE:ATKR
|
0.022x |
|
Jiangzhong Pharmaceutical Co Ltd
SHG:600750
|
-0.001x |
|
Ultragenyx
NASDAQ:RARE
|
0.860x |
|
Blackstone Mortgage Trust Inc
NYSE:BXMT
|
0.050x |
|
Nantong Haixing Electronics Co Ltd
SHG:603115
|
0.000x |
Annual Cash Flow Conversion Efficiency for TransMedics Group Inc (2006–2025)
The table below shows the annual cash flow conversion efficiency of TransMedics Group Inc from 2006 to 2025. For the full company profile with market capitalisation and key ratios, see market value of TransMedics Group Inc.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $473.10 Million | $192.84 Million | 0.408x | +90.93% |
| 2024-12-31 | $228.60 Million | $48.80 Million | 0.213x | +324.83% |
| 2023-12-31 | $137.20 Million | $-13.03 Million | -0.095x | +61.17% |
| 2022-12-31 | $187.38 Million | $-45.82 Million | -0.245x | +42.52% |
| 2021-12-31 | $67.85 Million | $-28.86 Million | -0.425x | -46.02% |
| 2020-12-31 | $103.89 Million | $-30.27 Million | -0.291x | +50.69% |
| 2019-12-31 | $54.65 Million | $-32.29 Million | -0.591x | -110.97% |
| 2018-12-31 | $-4.83 Million | $-25.98 Million | 5.385x | +3833.79% |
| 2017-12-31 | $-168.72 Million | $-23.10 Million | 0.137x | +122.03% |
| 2016-12-31 | $38.79 Million | $-24.11 Million | -0.622x | +66.36% |
| 2006-12-31 | $8.80 Million | $-16.27 Million | -1.847x | -- |
About TransMedics Group Inc
TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company provides Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic con… Read more